Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs

Anti-Cancer Drug Design

Volumn 12, Issue 8, 1997, Pages 659-670

  Kunkel, Mark W ^a   Kirkpatrick, D Lynn ^b   Johnson, Jill I ^c   Powis, Garth ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF REGINA   (Canada)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; COMPARE; Screening; Thioredoxin; Thioredoxin reductase

Indexed keywords

2 IMIDAZOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZYL 2 IMIDAZOLYL DISULFIDE; DISULFIDE; GLUTATHIONE REDUCTASE; INSULIN; IV 2; OXIDOREDUCTASE INHIBITOR; THIOREDOXIN; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

ALGORITHM; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DATA BASE; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PATTERN RECOGNITION; PRIORITY JOURNAL; REDUCTION;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DISULFIDES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; SIGNAL TRANSDUCTION; THIOREDOXIN REDUCTASE (NADPH); TUMOR CELLS, CULTURED;

EID: 0031466528     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. ALLEY, M.C., SCUDIERO, D.A., MONKS, A., HURSEY, M.L., CZERWINSKI, M.J , FINE, D.L., ABBOTT, B.J., MAYO, J.G., SHOEMAKER, R.H. & BOYD, M.R. (1988). Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Research, 48, 589.
2. ALVAREZ, M., PAULL, K., MONKS, A , HOSE, C., LEE, J.S., WEINSTEIN, J., GREVER, M., BATES, S. & FOJO, T. (1995). Generation of a drug resistance profile by quantification of mdr-1-P-glycoprotein in the cell lines of the National Cancer Institute anticancer drug screen. Journal of Clinical Investigation, 95, 2205.
3. BERGGREN, M., GALLEGOS, A., GASDASKA, J.R., GASDASKA, PY., WARNEKE, J. & POWIS, G. (1996). Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Research, 16, 3459.
4. COLMON, R.F & BLACK, s (1965). On the role of flavin adenine dinucleotide and thiol growth in the catalytic mechanism of yeast glutathione reductase. Journal of Biological Chemistry, 240, 1796.
5. ERICSON, M.L , HORLING, J., WENDEL-HANSEN, V., HOLMGREN, A & ROSEN, A. (1992). Secretion of thioredoxin after in vitro activation of human B cells. Lymphokine and Cytokine Research, 11, 201.
6. FITZSIMMONS, S.A., WORKMAN, P., GREVER, M., PAULL, K., CAMALIER, R & LEWIS, A.D. (1996). Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. Journal of the National Cancer Institute, 88, 259.
7. FUJII, S., NANBU, Y., NONOGAKI, H., KONISHI, I , MORI, T., MASUTANI, H. & YODOI, J. (1991). Coexpression of adult T-cell leukemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamous epithelium. Cancer, 68, 1583.
8. GALLEGOS, A., GASDASKA, J.R., GOODMAN, D., GASDASKA, P.Y., BERGGREN, M., BRIEHL, M.M. & POWIS, G. (1996). Transfection with human thioredoxin increases cell proliferation and a dominant negative mutant thioredoxin reverses the transformed phenotype of breast cancer cells. Cancer Research, 56, 5765.
9. GASDASKA, J.R., BERGGREN, M. & POWIS, G. (1995). Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth & Differentiation, 6, 1643.
10. GASDASKA, P.Y., OBLONG, J.E., COTGREAVE, I.A. & POWIS, G. (1994). The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. Biochimica et Biophysica Acta, 1218, 292.
11. GASDASKA, P.Y., GASDASKA, J.R., COCHRAN, S & POWIS, G. (1995). Cloning and sequencing of human thioredoxin reductase. FEBS Letters, 373, 5.
12. GRIPPO, J.F., TIENRUNGROJ, W., DAHMER, M.K., HOUSLEY, P.R. & PRATT, W.B. (1983). Evidence that the endogenous heat-stable glucocorticoid receptor-activating factor is thioredoxin. Journal of Biological Chemistry, 258, 13658.
13. LAURENT, TC., MOORE, E.C. & REICHARD, P. (1964). Enzymatic synthesis of deoxyribonucleotides VI. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B. Journal of Biological Chemistry, 239, 3436.
14. LEE, J.S., PAULL, K., ALVAREZ, M., HOSE, C., MONKS, A., GREVER, M., FOJO, A.T. & BATES, S. (1994). Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Molecular Pharmacology, 46, 627.
15. LUNDSTRÖM, J. & HOLMGREN, A. (1990). Protein disulfide-isomerase is a substrate for thioredoxin reductase and has thioredoxin-like activity. Journal of Biological Chemistry, 265, 9114.
16. LUTHMAN, M. & HOLMGREN, A (1982). Rat liver thioredoxin and thioredoxin reductase: purification and characterization. Biochemistry, 21, 6628.
17. MATTHEWS, J.R., WAKASUGI, N., VIRELIZIER, J.-L.. YODOI, J. & HAY, R.T. (1992). Thioredoxin regulates the DNA binding activity of NF-kappaB by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Research, 20, 3821.
18. MONKS, A., SCUDIERO, D., SKEHAN, P., SHOEMAKER, R., PAULL, K., VISTICA, D., HOSE, C , LANGLEY, J., CRONISE, P. & VAIGRO-WOLFF, A. (1991). Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. Journal of the National Cancer Institute, 83, 757.
19. NAKAMURA, H., MASUTANI, H., TAGAYA, Y., YAMAUCHI, A., INAMOTO, T., NANBU, Y., FUJII, S., OZAWA, K. & YODOI, J. (1992). Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma. Cancer, 69, 2091.
20. NISHIZUKA, Y (1992). Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C. Science, 258, 607.
21. OBLONG, J E , GASDASKA, P.Y., SHERRILL, K. & POWIS, G. (1993). Purification of human thioredoxin reductase: properties and characterization by absorption and circular dichroism spectroscopy. Biochemistry, 32, 7271.
22. OBLONG, J.E., BERGGREN, M , GASDASKA, P.Y & POWIS, G. (1994). Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin. Journal of Biological Chemistry, 269, 11714.
23. PAULL, K.D , SHOEMAKER, R.H., HODES, L., MONKS, A., SCUDIERO, D.A., RUBENSTEIN, K., PLOWMAN, J. & BOYD, M.R. (1989). Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. Journal of the National Cancer Institute, 81, 1088.
24. PAULL, K.D., LIN, C.M., MALSPEIS, L. & HAMEL, E. (1992). Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Research, 52, 3892.
25. POWIS, G., OBLONG, J.E., GASDASKA, P.Y., BERGGREN, M., HILL, S. & KIRKPATRICK, D.L. (1994). The thioredoxin/ thioredoxin reductase redox system and control of cell growth. Oncology Research, 6, 539.
26. POWIS, G., KIRKPATRICK, D.L., ANGULO, M., GASDASKA, J.R., POWELL, M.B., SALMON, S.E. & MONTFORT, W.R. (1996). Thioredoxin redox signalling: a novel target for anticancer drug development. Anticancer Drugs, 7 (Suppl. 3), 121.
27. RIONDEL, J., BERIEL, H., DARDAS, A., CARRAZ, G. & ODDOUX, L. (1981). Studies of antitumor activity of the culture filtrate of Hohenbuehelia geogenius (D.C. ex Fr.) Sing (Basidiomycete). Drug Research, 31, 293.
28. RUBARTELLI, A., BAJETTO, A., ALLAVENA, G., WOLLMAN, E. & SITIA, R. (1992). Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. Journal of Biological Chemistry, 267, 24161.
29. RUBARTELLI, A., BONIFACI, N. & SITIA, R. (1995). High rates of thioredoxin secretion correlate with growth arrest in hepatoma cells. Cancer Research, 55, 675.
30. WAKASUGI, N., TAGAYA, Y., WAKASUGI, A., MITSUI, M., MAEDA, M., YODOI, J. & TURSZ, T (1990). Adult T-Cell leukemia-derived factor/thioredoxin produced by both human T-lymphotropic virus type land Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergized with interleukin-1 and interleukin-2. Proceedings of the National Academy of Sciences, USA, 87, 8282.
31. WAKELAM, M.J.O., PETTIT, T.R., KAUR, P., BRISCOE, C.P., STEWART, A., PAUL, A., PATERSON, A., CROSS, M.J., GARDNER, S.D., CURRIE, S., MACNULTY, E.E , PLEVIN, R. & COOK, S.J. (1993). Phosphatidylcholine hydrolysis: a multiple messenger generating system. Advances in Second Messenger and Phosphoprotein Research
32. WEINSTEIN, J.N., MYERS, T.G., O'CONNOR, P.M., FRIEND, S.H., FORNACE, A.J., KOHN, K.W., FOJO, T., BATES, S.E., RUBINSTEIN, L.V., ANDERSON, N.L., BUOLAMWINI, J.K., VAN OSDOL, W.W., MONKS, A P., SCUDIERO, D.A., SAUSVILLE, E.A., ZAHAREVITZ, D.W., BUNOW, B., VISWANADHAN, VN, JOHNSON, G.S., WITTES, R R , & PAULL, K.D (1997) An information-intensive approach to the molecular pharmacology of cancer. Science, 275, 343.
33. YODOI, J. & TURSZ, T (1991). ADF, a growth-promoting factor dervied from adult T cell leukemia and homologous to thioredoxin: involvement in lymphocyte immortalization by HTLV-I and EBV. Advances in Cancer Research, 57, 381.